This Apple Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Analysts upgraded RSG, AAPL, MRCY, DK and DRTS, revising price targets, including AAPL to $425 and DRTS to $22.
Stocks · News reference
Alpha Tau Medical Receives FDA Approval For Investigational Device Exemption Supplement To Expand Its U.S. REGAIN Study
Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that the U.S. Food and Drug Administration (FDA) has
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Piper Sandler Upgrades Alpha Tau Medical to Overweight From Neutral
Investment firm Piper Sandler has upgraded Alpha Tau Medical Ltd. from Neutral to Overweight, setting a price target of $22.
Alpha Tau Medical Reports Financial and Operational Update
Alpha Tau Medical announced that its 2023 net loss narrowed to $29.2 million, supported by clinical progress and a cash position of $84.9 million.
Alpha Tau Medical Announces Inclusion in Tel Aviv Stock Exchange Indices
Alpha Tau Medical Ltd. announced that its ordinary shares will be included in the TA-90 and TA-125 indices of the Tel Aviv Stock Exchange, effective November 5, 2026.
Alpha Tau Medical and Samsung Medical Center Sign MOU for Pancreatic Cancer Clinical Trial
Alpha Tau Medical has entered into a Memorandum of Understanding (MOU) with Samsung Medical Center to explore a clinical trial of its Alpha DaRT technology for treating pancreatic cancer patients in Korea.
HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $16 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $16 price target.